Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled time : 15:20 save search
HI-Bio Receives FDA Orphan Drug Designation for Felzartamab for the Treatment of Membranous Nephropathy
Published: 2023-05-25 (Crawled : 15:20) - biospace.com/
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.97%
fda nephropathy drug treatment designation
Gastrointestinal Bleeding Treatment Market Size, Share & Trends Analysis: Global Industry Size Is Predicted to Grow USD 1092 Million by 2030, at a CAGR of likely 4.56%
Published: 2023-04-28 (Crawled : 15:20) - prnewswire.com
CNMD | $72.64 2.2% 0.0% 500K
|
Health Technology
|
| O: -0.92%
H: 0.79%
C: -1.13%
BSX | $67.33 -0.13% -0.31% 7M
|
Health Technology
|
| O: -0.29%
H: 1.89%
C: 0.46%
CNMD | $72.64 2.2% -1.98% 500K
|
Health Technology
|
| O: -0.92%
H: 0.79%
C: -1.13%
bleeding treatment global trends gastrointestinal market
Water and Wastewater Treatment Market for Food & Beverage Industry to Reach $78.35 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®
Published: 2023-02-21 (Crawled : 15:20) - prnewswire.com
GFL | $33.15 0.39% 0.0% 830K
|
Transportation
|
| O: -1.16%
H: 0.64%
C: -2.45%
DD | News | $73.89 0.49% 0.0% 2.3M
|
Process Industries
|
| O: -1.01%
H: 0.66%
C: -1.83%
MMM | $92.27 0.86% -0.18% 3.6M
|
Producer Manufacturing
|
| O: -0.88%
H: 0.36%
C: -2.46%
covid-19 research water treatment trends report impact food market
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
Published: 2023-02-15 (Crawled : 15:20) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 2.34%
H: 9.2%
C: 8.45%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.34%
H: 0.14%
C: -0.06%
eb613 treatment meeting review osteoporosis
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossExpects to Commence Phase 2a of CAReS During the First Quarter of 2023
Published: 2023-02-02 (Crawled : 15:20) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -2.3%
H: 2.11%
C: 1.78%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.31%
H: 0.05%
C: -0.33%
ARTL | $1.28 -1.94% 5.5K
|
Health Technology
|
| O: -1.27%
H: 1.67%
C: -0.96%
art27 treatment cares trial art27.13 phase 2b
Hebrew University' Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023
Published: 2023-01-25 (Crawled : 15:20) - biospace.com/
CMND | $1.22 3.56% 3.43% 110K
|
n/a
|
| O: 6.31%
H: 12.35%
C: -7.36%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.68%
H: 1.4%
C: 1.4%
treatment obesity biotech
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
Published: 2023-01-19 (Crawled : 15:20) - biospace.com/
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -0.13%
H: 1.27%
C: -1.85%
treatment fda fibrosis drug liver application nash
Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
Published: 2023-01-06 (Crawled : 15:20) - biospace.com/
NOVN | $0.0941 -24.84% -32.91% 7.2M
|
Health Technology
|
| O: 0.0%
H: 1.96%
C: -26.96%
LGND | $72.59 0.1% 0.1% 140K
|
Health Technology
|
| O: 0.59%
H: 1.57%
C: 0.17%
sb206 molluscum treatment fda drug application
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
Published: 2022-12-19 (Crawled : 15:20) - biospace.com/
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: -0.75%
H: 1.01%
C: -7.01%
zoryve treatment drug children application psoriasis
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
Published: 2022-12-08 (Crawled : 15:20) - biospace.com/
YMAB | $15.15 1.0% 0.99% 470K
|
Health Technology
|
| O: 0.22%
H: 3.45%
C: -0.86%
danyelza treatment approved china
ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV
Published: 2022-10-25 (Crawled : 15:20) - biospace.com/
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 5.27%
H: 0.0%
C: -2.17%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.59%
H: 1.21%
C: 0.71%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.57%
H: 1.16%
C: 0.94%
offering treatment antibody hiv potential positive
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Published: 2022-10-14 (Crawled : 15:20) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: 3.76%
H: 0.47%
C: -9.9%
treatment disease chmp approval
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
Published: 2022-10-12 (Crawled : 15:20) - globenewswire.com
CMPS | $8.35 -0.83% -0.84% 370K
|
Health Technology
|
| O: -2.4%
H: 2.11%
C: -5.44%
comp360 day treatment program depression
GentiBio Announces Preclinical Data Showing Antigen Specific Engineered Tregs Suppressing Pancreatic Inflammation and Potential Utility for Treatment and Prevention of Clinical Type 1 Diabetes (T1D)
Published: 2022-10-11 (Crawled : 15:20) - prnewswire.com
IBIO | $1.72 -2.83% 0.0% 95K
|
Health Technology
|
| O: -1.15%
H: 0.0%
C: -17.67%
treatment preclinical diabetes potential pancreatic
Arizona Oncology Cancer Center working with NexCore Group on new cancer treatment center
Published: 2022-10-06 (Crawled : 15:20) - prnewswire.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 4.3%
H: 0.0%
C: -9.09%
treatment cancer group
Memorandum of Understanding Signed by Miranda Water Treatment Systems and Rainmaker Worldwide Inc.
Published: 2022-10-05 (Crawled : 15:20) - globenewswire.com
RAKR | $0.0018 40.0% 2.4M
|
|
| O: 12.5%
H: 48.89%
C: 44.44%
water treatment
Europe Air Treatment Market to Reach $3.16 Billion by 2028
Published: 2022-10-03 (Crawled : 15:20) - prnewswire.com
IR | News | $88.4 -0.64% 0.0% 2.5M
|
Producer Manufacturing
|
| O: 1.94%
H: 3.71%
C: 2.11%
DCI | $71.91 0.36% 0.0% 460K
|
Process Industries
|
| O: 1.49%
H: 2.17%
C: 1.67%
treatment europe air market
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
Published: 2022-09-19 (Crawled : 15:20) - ir.auriniapharma.com
AUPH | $5.01 4.16% 3.99% 1.6M
|
Health Technology
|
| O: -1.1%
H: 6.44%
C: 5.82%
lupkynis treatment lupus approval
Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings
Published: 2022-09-12 (Crawled : 15:20) - biospace.com/
NTRA S | $85.275 -2.3% -2.35% 2.5M
|
Health Services
|
| O: 1.25%
H: 0.0%
C: -0.5%
treatment cancer
Statistics on Global Retinal Disorder Treatment Market Size & Share to Surpass USD 15675.74 Million by 2028, Exhibit a CAGR of 7.30% | Industry Trends, Value, Analysis & Forecast Report by Zion Market Research
Published: 2022-07-29 (Crawled : 15:20) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -1.22%
H: 0.41%
C: -0.14%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.32%
H: 0.3%
C: -0.1%
treatment research global report market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.